Prosecution Insights
Last updated: April 19, 2026

BLUEPRINT MEDICINES CORPORATION

6 pending office actions

Portfolio Summary

6
Total Pending OAs
1
Final Rejections
5
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18573222 SALT AND CRYSTAL FORMS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR ENGLISH, CONNOR KENNEDY 1625 Non-Final OA Dec 21, 2023
18572867 EGFR INHIBITORS ROMERO, KRISTEN WANG 1624 Non-Final OA Dec 21, 2023
18284943 DIAZEPANONE-FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF BORALSKY, LUKE ALAN 1624 Non-Final OA Sep 29, 2023
18033931 PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF HERNANDEZ, JACKSON J 1627 Final Rejection Apr 26, 2023
18031714 COMPOSITIONS AND METHODS FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES HIRAKIS, SOPHIA P 1623 Non-Final OA Apr 13, 2023
18031688 COMPOSITIONS AND METHODS FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES TOWNSLEY, SARA ELIZABETH 1629 Non-Final OA Apr 13, 2023

Managing BLUEPRINT MEDICINES CORPORATION's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month